Combination therapy with oxaliplatin provided consistently improved outcomes without adversely affecting post-relapse survival in the adjuvant treatment of stage III colon cancer , irrespective of whether the fluoropyrimidine backbone was capecitabine or leucovorin and fluorouracil .